10-Year Free Cash Flow Projections(showing years 1, 3, 5, 7, 10)
| Year | Year 1 | Year 3 | Year 5 | Year 7 | Year 10 |
|---|
| Revenue | $2.0B | $3.1B | $6.9B | $10.6B | $13.6B |
| EBIT | -$503M | -$776M | -$1.7B | -$2.2B | -$2.0B |
| Tax | -$106M | -$163M | -$358M | -$459M | -$420M |
| NOPAT | -$397M | -$613M | -$1.3B | -$1.7B | -$1.6B |
| + Depreciation | $336M | $518M | $1.1B | $1.7B | $2.2B |
| - Capex | $551M | $851M | $1.9B | $2.9B | $3.7B |
| - Δ NWC | $37M | $309M | $694M | $742M | $162M |
| Free Cash Flow | -$650M | -$1.3B | -$2.8B | -$3.6B | -$3.2B |
| Discount Factor | 0.908 | 0.748 | 0.616 | 0.508 | 0.380 |
| Present Value | -$590M | -$939M | -$1.7B | -$1.8B | -$1.2B |
FCF Formula: Free Cash Flow = NOPAT + Depreciation - Capex - Change in Net Working Capital
Sensitivity AnalysisPrice per Share
| WACC ↓ / Growth → | 2.00% | 2.50% | 3.00% | 3.50% | 4.00% |
|---|
| 8.16% | $-93.78 | $-99.56 | $-106.46 | $-114.84 | $-125.23 |
| 9.16% | $-80.49 | $-84.39 | $-88.91 | $-94.23 | $-100.58 |
| 10.16% | $-70.85 | $-73.59 | $-76.71 | $-80.29 | $-84.46 |
| 11.16% | $-63.63 | $-65.62 | $-67.85 | $-70.37 | $-73.24 |
| 12.16% | $-58.08 | $-59.57 | $-61.21 | $-63.04 | $-65.10 |
How to read: This table shows how the valuation changes with different WACC (discount rate) and terminal growth rate assumptions. Green = undervalued, Red = overvalued.
Key Assumptions & Drivers✓ Using Analyst Consensus Estimates• Healthcare Sector
Growth Assumptions (Select Years)
Year 1 Revenue Growth4.64%
Year 3 Revenue Growth31.66%
Year 5 Revenue Growth32.54%
Year 7 Revenue Growth20.72%
Year 10 Revenue Growth3.00%
Terminal Growth Rate3.00%
Margin & Efficiency
EBIT Margin-24.72%
Tax Rate21.00%
Capex / Revenue27.10%
NWC / Revenue40.96%
Key Drivers: Revenue growth, operating margin expansion, capex efficiency, and working capital management are the primary drivers of cash flow generation. Terminal value assumptions significantly impact final valuation.
Institutional-Grade Methodology
Actual Company Data: Revenue, EBIT, Capex, NWC, Tax Rate, Interest Expense, Beta
Market Assumptions: Risk-free: 4.5% (10Y), MRP: 4.5% (Damodaran 2026), Exit: 18x EV/EBITDA (S&P 500: 22x P/E)
This DCF model is for informational purposes only. Projections are based on assumptions that may not materialize. Past performance does not guarantee future results. Consult a financial advisor before making investment decisions.